Psychedelics have been growing in popularity across North America for recreational and therapeutic use, with celebrities like ...

The most common side effects of INVEGA HAFYERA® include: injection site reactions, weight gain, headache, upper respiratory ...

The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...

Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

Chronic Schizophrenia: Insomnia, Suicidal Ideation, and Psychopathology In a secondary analysis, U.S.-based researchers examined longitudinal associations over 3 months between suicidal ideation ...

"Schizophrenia is a leading cause of disability worldwide. It is a severe, chronic mental illness that is often damaging to a person's quality of life," she added. The drug has no boxed warning ...

Among individuals with schizophrenia, the risk for natural-cause mortality was increased in those with reduced cognitive functioning.

The death of a mother at the hands of her son was described as “tragic” by a Calgary judge, who found the 32-year-old not criminally responsible.

Brodmann area 22, namely the superior temporal gyrus, had a greater number of abnormally expressed genes in both diseases; moreover, genes that differentiated AD and schizophrenia patients from ...

Intra-Cellular Therapies' lumateperone shows significant efficacy in reducing schizophrenia relapse rates, with a 63% risk ...

(RTTNews) - Intra-Cellular Therapies, Inc. (ITCI), Tuesday announced positive data from phase 3 trial of Lumateperone, marketed as Caplyta, for the prevention of relapse in adult patients with ...